A new study has identified several trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.
A new study has identified several interesting trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.
The study, published in Cancer, found that Asians were the only group that has a decreasing incidence of HCC, a trend likely due to a shift from advanced disease to more localized disease. In contrast, blacks, Hispanics, and non-Hispanic whites all had increasing rates of HCC.
“Although the overall incidence of total HCC seems to have peaked and plateaued beginning in 2009, the prevalence of total HCC has continued rising since 2003,” wrote researchers led by John Ha, MD, of Alameda Health System-Highland Hospital in Oakland, California. “The disparate trends in HCC incidence and prevalence in the most recent era reflect 2 major improvements in the management of HCC: 1) improved identification and treatment of underlying liver disease etiologies that can lead to HCC, and 2) improved HCC screening and surveillance programs that contribute to early detection and thereby improved treatment and long-term survival outcomes.”
Using data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry, the researchers investigated race-specific disparities in HCC incidence and survival from 51,741 patients with HCC from 2003 to 2011. The median follow-up was 8 months.
During this time, they found that Asians had the highest incidence of HCC (18.6 per 100,000 persons per year). This was followed by blacks (15.7 per 100,000), Hispanics (11.8 per 100,000), and non-Hispanic whites (7.0 per 100,000). Asian men had the highest incidence overall of any group (28.9 per 100,000).
Although Asians had the highest incidence, Hispanics saw the greatest increase in rates during this time period (35.8%). In contrast, the rates among Asians decreased by 5.5%. According to the researchers, “This observation likely reflects improvements in the management of chronic hepatitis B virus, which translate into a reduced incidence of hepatitis B virus–related HCC.”
Looking at 5-year HCC survival, the researchers found the highest survival rate among Asians (26.1%) and the lowest among blacks (21.3%). A multivariable regression analysis showed that Asians had a 17% higher rate of survival (hazard ratio [HR], 0.83 [95% CI, 0.79–0.87]; P < .001), and blacks had a 6% higher rate of survival (HR, 0.94 [95% CI, 0.89–0.99]; P = .01) compared with non-Hispanic whites.
“Greater research is needed to better understand these race/ethnicity-specific disparities and how to ensure equitable implementation of HCC screening, surveillance, and treatment programs across all groups to improve long-term HCC outcomes,” the researchers wrote.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer
February 18th 2024Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma
February 7th 2024Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.